Efficacy of tegileridine combined with intercostal nerve block for postoperative analgesia following thoracoscopic pulmonary resection: a study protocol for a randomised controlled trial Authors: Hongbo Zheng, Ruochen Pan, Fan Yuan, Jingyi Li, Aijun Xu Published: 2026 ABSTRACT AbstractBackgroundPatients undergoing thoracoscopic pulmonary resection are prone to moderate-to-severe acute postoperative pain, which not only increases the risk of pulmonary complications but may also lead to chronic postsurgical pain. While traditional opioids provide effective analgesia, they are associated with significant adverse effects. Intercostal nerve block (ICNB) can precisely relieve incisional pain but has a limited duration of action. Tegileridine is a novel biased μ-opioid receptor agonist, offering favourable analgesic efficacy with fewer adverse reactions. Currently, there is a lack of research on the combination of tegileridine and ICNB for analgesia following thoracoscopic pulmonary resection, warranting further clinical exploration.Methods and analysisThis single-centre, randomised, double-blind, non-inferiority trial is designed to compare the postoperative analgesic efficacy of tegileridine-based patient-controlled intravenous analgesia (PCIA) combined with ICNB versus sufentanil-based PCIA combined with ICNB in patients undergoing thoracoscopic pulmonary resection. A total of 118 participants are enrolled and randomly assigned in a 1:1 ratio to either the tegileridine group or the sufentanil group. The primary outcome is the pain Visual Analogue Scale score during movement within 48 hours postoperatively, with non-inferiority determined using a margin of –1 point and 95% CIs. Secondary outcomes include the number of rescue analgesic interventions, PCIA-related parameters (total analgesic consumption, number of effective presses and total number of presses), incidence of opioid-related adverse events (respiratory depression, postoperative nausea and vomiting) and overall patient satisfaction.Ethics and disseminationThe trial protocol was approved by the Medical Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology on 14 February 2026 (Approval No. 2026-S010). The findings will be disseminated through publication in a peer-reviewed journal and on relevant institutional websites.Trial registration numberNCT07386626. STRENGTHS AND LIMITATIONS OF THIS STUDY Patients, anaesthesiologists, surgeons, outcome assessors and statistical analysts are all blinded to group assignment, minimising bias. Patients, anaesthesiologists, surgeons, outcome assessors and statistical analysts are all blinded to group assignment, minimising bias. All surgical patients are recruited from the same clinical team, with standardised surgical protocols and uniform postoperative management, limiting procedural variability. All surgical patients are recruited from the same clinical team, with standardised surgical protocols and uniform postoperative management, limiting procedural variability. The single-centre design and enrolment from a single clinical team may limit generalisability to other settings or heterogeneous populations. The single-centre design and enrolment from a single clinical team may limit generalisability to other settings or heterogeneous populations. The absence of dose-controlled trials makes it difficult to accurately assess the incidence of dose-related adverse reactions. The absence of dose-controlled trials makes it difficult to accurately assess the incidence of dose-related adverse reactions. Introduction Thoracoscopic surgery has emerged as the standard surgical approach for early-stage lung cancer and benign pulmonary lesions due to its minimally invasive nature and faster recovery.1 2 However, postoperative pain remains a significant challenge even with minimally invasive techniques. The incidence of moderate-to-severe acute postoperative pain among Chinese surgical patients is 48.7%, rising to 62.9% in thoracic surgery.3 4 Such pain represents a complex, multifactorial pathophysiological process that adversely affects perioperative safety and long-term prognosis.57 Inadequately controlled acute pain after thoracoscopic surgery can suppress coughing and deep breathing, increasing the risk of respiratory complications such as atelectasis and pulmonary infection,4 7 and is a major independent risk factor for chronic postsurgical pain (CPSP).4 8 Recent studies indicate that moderate-to-severe pain significantly elevates the risk of troponin elevation and perioperative myocardial injury.9 Effective postoperative analgesia in thoracic surgery remains challenging. The prevalent approach relies on systemic opioids (eg, morphine, sufentanil) delivered via patient-controlled intravenous analgesia (PCIA). However, traditional μ-receptor agonists frequently cause adverse effects including respiratory depression, postoperative nausea and vomiting (PONV), constipation and addiction mediated through activation of the β-arrestin pathway.3 4 Despite the widespread use of sufentanil or morphine PCIA, over 50% of patients still experience moderate-to-severe resting pain.3 Evidence suggests that a multimodal strategy combining PCIA with peripheral regional nerve blocks improves analgesia while reducing intravenous opioid consumption and adverse effects.3 4 Thoracoscopically guided intercostal nerve block (ICNB) offers a technically straightforward alternative that avoids risks such as bleeding, infection and pneumothorax associated with ultrasound-guided paravertebral or intercostal approaches, and effectively addresses somatic pain after thoracoscopic pulmonary resection.1012 Tegileridine is a highly selective biased agonist of the μ-opioid receptor. Its innovation lies in preferential activation of the G-protein pathway—mediating analgesia—with minimal activation of the β-arrestin-2 pathway linked to respiratory depression and gastrointestinal dysfunction.1315 Thus, it maintains potent analgesia while markedly reducing typical opioid-related side effects. Combining ICNB with tegileridine-based PCIA may offer an ideal, complementary analgesic model. To date, no studies have evaluated tegileridine combined with ICNB for analgesia after thoracoscopic pulmonary resection. To assess the efficacy and safety of this novel multimodal regimen, we have designed a randomised controlled trial comparing tegileridine with sufentanil. We hypothesise that tegileridine is non-inferior to sufentanil and yields comparable or lower pain scores and adverse event rates within 48 hours postoperatively. The findings may support tegileridine combined with ICNB as a safer and more effective analgesic alternative after thoracoscopic pulmonary resection. Method and analysis Study design and ethical considerations This study is a single-centre, randomised, double-blind, non-inferiority trial designed to compare the postoperative analgesic efficacy of tegileridine combined with ICNB versus sufentanil combined with ICNB in patients undergoing thoracoscopic pulmonary resection. The study is conducted in accordance with the principles of the Declaration of Helsinki and adheres to the International Council for Harmonisation Good Clinical Practice (GCP) guidelines.1315 The trial protocol is reported in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) reporting guidelines16 and has been registered accordingly. The analgesic regimens—PCIA with tegileridine or sufentanil combined with ICNB—reflect standard clinical practices. Throughout the study, patients undergo continuous vital signs monitoring to enable prompt prevention and management of potential respiratory or cardiovascular complications. Both analgesics are commonly used in clinical practice. Although sufentanil may cause opioid-related adverse events such as respiratory depression and PONV, these can be effectively managed through close monitoring and standardised treatment. As tegileridine is an investigational drug, its safety profile will be further evaluated in this study, and all adverse events will be documented and managed according to standard procedures. All participants will receive a detailed introduction to the study from the research team before enrolment and will provide written informed consent (see online supplemental material). Participants may withdraw from the study at any time without providing a reason, and such withdrawal will not affect their subsequent routine care. All personal information collected will be anonymised and subject to strict confidentiality measures; data will be used solely for study-related analyses to protect participant privacy. Study objectives The primary objective of this study is to evaluate whether the tegileridine PCIA combined with ICNB regimen is non-inferior to the sufentanil PCIA combined with ICNB regimen for postoperative analgesia in patients undergoing thoracoscopic pulmonary resection. Secondary objectives include assessment of safety, recovery indicators, patient sleep quality and overall satisfaction, with the aim of providing a safer and more effective postoperative analgesia option for this patient population. Participants Inclusion criteria are patients aged 18 to 75 years who are scheduled for thoracoscopic pulmonary resection, have an American Society of Anesthesiologists (ASA) physical status classification of I to III, have a body mass index ranging from 18 to 30 kg/m², and voluntarily enrol and provide written informed consent. Exclusion criteria are alcohol dependence; chronic analgesic use or ongoing treatment for acute or chronic pain; pregnancy or lactation; allergy or contraindication to any study medication including anaesthetics, analgesics and antiemetics; severe sleep apnoea syndrome; acute or severe bronchial asthma; psychiatric or neurological disorders; cognitive impairment; known or suspected gastrointestinal obstruction; severe hepatic or renal dysfunction such as Child-Pugh class C; chronic obstructive pulmonary disease; major cardiovascular disease; or investigator’s judgement of unsuitability for participation or participant refusal. Sample size calculation Sample size is estimated based on the primary outcome, defined as the mean pain visual analogue scale (VAS, 0–10) scores during movement at seven time points (post-anaesthesia care unit, 1, 6, 12, 24, 36 and 48 hours postoperatively) within the 48-hour postoperative period, with the non-inferiority margin (Δ) set at 1.0 point, consistent with the minimal clinically important difference for VAS in acute postoperative pain studies identified by Myles et al.17 According to preliminary results, the VAS score in the sufentanil group was 4.08±1.78. Since the pooled SD of the two groups is not calculated in the preliminary study and assuming comparable variability between the two groups, the SD from the control group (σ = 1.78) is used as an estimate of the pooled SD—a variability similar to that reported in thoracic surgery populations by Kim et al18 and Semyonov et al.19 Under a one-sided significance level of α = 0.025 and a power of 80%, at least 50 evaluable patients per group (100 in total) are required. Accounting for an estimated 15% dropout rate, 59 patients per group (118 in total) are enrolled. Recruitment Subject recruitment will be conducted in the Department of Thoracic Surgery, Tongji Hospital. To minimise selection bias, this study will employ consecutive sampling, whereby all patients who meet the inclusion criteria will be invited in order; these patients will be screened during preoperative evaluations. Any patient meeting any of the exclusion criteria will not be enrolled. Before obtaining signed informed consent, the research team will provide a detailed explanation of the study purpose, procedures, potential benefits and risks. When necessary, plain language, visual aids or family assistance may be used to ensure that patients fully understand the study content. A screening log will document the number of patients assessed, the number enrolled and the reasons for non-participation. Blinding and randomisation This is a double-blind trial. An independent statistician will generate the randomisation scheme using SPSS 26.0 in two steps. In the first step, a fixed seed (eg, 20260216) will be used to generate random numbers between 0 and 1 for 118 participants. Following sorting, the first 59 participants will be assigned to the tegileridine group and the remaining 59 to the sufentanil group (1:1 allocation). In the second step, a second set of random numbers between 0 and 1 will be generated using another fixed seed (eg, 20260309). Following sorting, the order (1–118) will serve as the envelope numbers. Thus, the first random numbers determine group assignment, and the second random numbers determine envelope numbers. The group allocation results will be sealed in opaque envelopes numbered accordingly, ensuring that envelope numbers are not associated with group assignment.20 A post-anaesthesia care unit (PACU) nurse who is not involved in clinical assessment will open the envelope 50 min before the end of surgery to prepare the postoperative loading dose and analgesic pump based on the patient’s weight. The analgesic solutions in both groups will be identical in appearance and volume. Throughout the trial, patients, anaesthesiologists, surgeons, outcome assessors and data analysts will remain blinded to group allocation.14 20 Interventions As illustrated in figure 1, all participants are randomly assigned to two groups and receive enhanced recovery after surgery (ERAS)-based perioperative care. The recommended minimum preoperative fasting period is 6 hours for solid foods and 2 hours for clear fluids. After verifying patient identity, surgical site and procedure, intravenous access is established and balanced crystalloid infusion is initiated at 4 mL/kg/hour. Monitoring includes electrocardiography, blood pressure, pulse oximetry (SpO₂) and ultrasound-guided radial arterial catheterisation for invasive blood pressure measurement. Patient flowchart according to CONSORT guidelines. n values will be reported after study completion. CONSORT, Consolidated Standards of Reporting Trials; FAS, full analysis set; PPS, per protocol set. 5 minutes before anaesthesia induction, penehyclidine 0.01 mg/kg (half dose for patients aged ≥65 years), dexamethasone 5 mg and palonosetron 0.05 mg are administered intravenously. Induction is performed with sufentanil 0.5–0.6 µg/kg, etomidate or remimazolam 0.3 mg/kg and cisatracurium 0.15–0.2 mg/kg. A double-lumen bronchial tube is then inserted orally under video laryngoscopy guidance, and its position is adjusted under fibreoptic bronchoscopy guidance. Mechanical ventilation is used to maintain EtCO₂ at 35–45 mmHg, while haemodynamic parameters are kept within ±20% of baseline. Anaesthesia is maintained with sevoflurane 1–2%, remifentanil 0.1–0.15 µg/kg/min and propofol 3–4 mg/kg/hour. Neuromuscular blockers are added as required. Depth of anaesthesia is titrated to maintain bispectral index between 40 and 55, guided by surgical stimulation. Forty minutes before surgery completion, patients in the tegileridine group will receive intravenous tegileridine (15 µg/kg, upper limit 1000 µg), whereas those in the sufentanil group will receive sufentanil (0.15 µg/kg, upper limit 10 µg). Before chest closure, an ICNB will be performed under thoracoscopic vision by injecting 3 mL of 0.4% ropivacaine into the fourth, fifth, sixth and seventh intercostal spaces. In the PACU, PCIA will be initiated using the same pump settings (bolus dose: 1 mL, lockout interval: 10 min, background infusion: 1 mL/hour), with each group receiving a 150 mL solution containing either tegileridine (100 µg/mL) or sufentanil (1 µg/mL). This study follows our hospital’s postoperative pain management protocol. Patients undergoing thoracic surgery routinely receive PCIA for 48 hours. The device will be retrieved by the clinical nurse in accordance with hospital policy, and relevant data will be recorded. Any remaining analgesic solution will be disposed of in line with China’s Regulations on the Administration of Narcotic Drugs and Psychotropic Substances. Note: The dosage selection of the investigational drug in this study is based on the following. According to previous research, the equianalgesic dose ratio of tegileridine to morphine is approximately 1:8 to 1:9,15 while that of sufentanil to morphine is approximately 1:800 to 1:1000.21 Based on equivalence conversion, the approximate equianalgesic dose ratio of tegileridine to sufentanil is 100:1, that is, 100 µg of tegileridine is approximately equivalent to 1 µg of sufentanil. Rescue protocol and unblinding All participants will receive standardised preoperative education on PCIA pump use, with instructions to self-administer a bolus when the movement-associated VAS score reaches ≥4. If pain (VAS≥4) persists 15–30 min after bolus delivery, the follow-up investigator may be contacted to provide rescue analgesia (intravenous flurbiprofen 50 mg, rectal diclofenac sodium 50 mg or oral loxoprofen-codeine). If analgesia remains insufficient, the anaesthesiology follow-up staff may adjust bolus or infusion doses as clinically indicated. For serious adverse events requiring unblinding (eg, severe allergy, intense pruritus, respiratory depression), the nurse may disclose group allocation to the principal investigator; the reason for unblinding will be documented in the case report form. Outcome measures The primary outcome is the VAS score for pain assessed under dynamic conditions in the PACU and at 1, 6, 12, 24, 36 and 48 hours postoperatively. Scores range from 0 to 10, with higher scores indicating more severe pain. Secondary outcomes include (1) the number of rescue analgesic interventions and the total dosage of remedial analgesic drugs; (2) PCIA-related parameters, including total analgesic consumption, number of effective presses and total number of presses; (3) the incidence of opioid-related adverse events, such as respiratory depression, dizziness, PONV, pruritus and delayed recovery of gastrointestinal function; and (4) prognostic indicators, including length of postoperative hospital stay, quality of sleep and overall patient satisfaction with the analgesia regimen. Data collection and management Preoperative data will include baseline characteristics (name, sex, age, height, weight, hospital identification number), ASA physical status, comorbidities (hypertension, coronary artery disease, diabetes, respiratory diseases), clinical diagnosis and surgical procedure. Postoperative data will include the loading dose administered, 48-hour VAS pain scores, rescue analgesia details, PCIA data, occurrence of adverse events, prognostic indicators and patient satisfaction scores. All data will be recorded by GCP-trained investigators using standardised case report forms. The research team will include two dedicated anaesthesia follow-up staff members responsible for double independent data entry with cross-verification. If any abnormal data are identified, the system will automatically perform range checks. Relevant personnel will promptly investigate the causes, conduct root cause analysis and document the complete handling process in the case report forms. Monitoring, assessment and management of adverse events This study will prioritise harm prevention, safety evaluation and adverse event monitoring. Adverse event severity will be assessed using the Accordion Severity Grading System and CTCAE v4.0 criteria (grades 0–5).22 If a serious adverse event related to the intervention occurs (eg, severe allergic reaction, respiratory depression, PONV or bradycardia), the research team will promptly intervene by discontinuing the suspected drug, providing free appropriate treatment (eg, antihistamines, opioid antagonists, antiemetics) and terminating the trial if necessary. Related hospitalisation costs will be compensated. All serious or unexpected adverse events will be documented in detail and reported promptly to regulatory authorities and the ethics committee as required. These events will be analysed periodically to determine whether to continue, modify or terminate the trial. Study monitoring Monitoring will be collaboratively overseen by the hospital’s Data Safety Office and the Ethics Committee. The Data Safety Office will conduct centralised data reviews every 1–2 months, with a focus on critical data and documents. Any serious adverse event related to the intervention must be reported promptly in writing to the hospital and the Ethics Committee, and appropriate interventions will be taken if necessary. Any modifications to the study protocol must be approved by the Ethics Committee before implementation. Statistical analysis Statistical analyses will be performed using SPSS V.26.0 and R software (nlme/lme4). The primary analysis will be conducted in the full analysis set (FAS), which adheres to the intention-to-treat principle and includes all randomised patients who received at least one dose of the study intervention and who had available outcome data. Additionally, a per-protocol set (PPS) analysis, comprising patients who completed the intervention according to the protocol without major deviations (figure 1), will be performed to assess the consistency of the results.20 For missing data, multiple imputation will be employed if the missing rate for the primary outcome exceeds 5%. Baseline characteristics will be summarised using mean±SD for continuous variables and frequencies with percentages for categorical variables. Primary analysis Analysis of covariance (ANCOVA) will be performed with the individual mean VAS score averaged over the 48-hour postoperative period as the primary outcome, adjusting for baseline VAS to estimate the between-group difference and its 95% CI (table 1). A one-sided significance level of α=0.025 will be used. Table 1Non-inferiority analysis of analgesic efficacyAnalysis methodOutcome measureBetween-group difference (95% CI)Non-inferiority marginCriterionConclusionPrimary analysisANCOVAMean VAS (48 hours)— (—, —)Δ=1.0 point95% CI lower bound>−1.0EstablishedSensitivity analysisMMRMMean VAS (48 hours)— (—, —)Δ=1.0 point95% CI lower bound>−1.0EstablishedSensitivity analysisMMRMVAS (12 hours)— (—, —)Δ=1.0 point95% CI lower bound>−1.0EstablishedSensitivity analysisMMRMVAS (36 hours)— (—, —)Δ=1.0 point95% CI lower bound>−1.0EstablishedANCOVA, analysis of covariance; MMRM, mixed model for repeated measures; VAS, visual analogue scale. Non-inferiority analysis of analgesic efficacy ANCOVA, analysis of covariance; MMRM, mixed model for repeated measures; VAS, visual analogue scale. Sensitivity analysis A mixed-effects model for repeated measures will be constructed to assess robustness, including fixed effects for group, time point and their interaction, with baseline VAS as a covariate. Both the between-group difference for the overall mean VAS score over the 48-hour postoperative period and the differences at key time points (12 hours, 36 hours) will be estimated (table 1). Secondary outcomes Secondary outcomes will be analysed using the FAS, with the PPS used for validation when necessary. Continuous outcomes will be analysed using independent samples t-test or Wilcoxon rank-sum test, and categorical outcomes using Pearson’s chi-square or Fisher’s exact test. Secondary outcomes will be analysed in an exploratory manner, with two-sided p<0.05 considered statistically significant. The Benjamini-Hochberg procedure will be applied to control the false discovery rate (Q<0.05) for outcome sets such as adverse events.20 Patient and public involvement Patients and the public will not be involved in the design, conduct, analysis or reporting of this study. Prior to protocol development, we interviewed patients, thoracic surgery teams and nursing staff to identify key analgesia-related outcomes. During postoperative analgesia, six ward follow-ups will involve active patient participation, and family enquiries will be addressed. Findings will be disseminated through publication, and telephone enquiries are welcome. Ethics and dissemination Ethical approval was obtained from the Medical Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology on 14 February 2026 (Approval No. 2026-S010). The study is registered with ClinicalTrials.gov and can be accessed online at https://clinicaltrials.gov/study/NCT07386626. Any protocol modifications will be approved by the relevant ethics review boards. The findings will be disseminated through publication in a peer-reviewed journal and presentation at relevant academic conferences. Study status The study is planned to start in March 2026 and is expected to be completed by January 2027, including patient enrolment, follow-up and data analysis. Discussion Postoperative pain following thoracoscopic pulmonary resection is not limited to incisional pain; it represents a complex pain syndrome comprising visceral pain, incisional pain, intercostal neuralgia, referred shoulder pain, pleural pain and drain-related discomfort, often manifesting as breathing-associated pain. Inadequate analgesia may contribute to the development of CPSP, which significantly impairs patients’ quality of life.3 23 Sufentanil is a potent analgesic commonly used after thoracic surgery. However, it carries dose-related adverse effects such as respiratory depression, PONV, pruritus and gastrointestinal inhibition.2427 These side effects may hinder early postoperative mobilisation and sleep quality. Furthermore, the relatively high incidence of adverse reactions limits its applicability in ERAS pathways. Xu et al reported that the incidence of adverse reactions associated with sufentanil use for post-cardiac surgery analgesia was 19.23%, with common adverse events including PONV, itching and dizziness.24 Whiting et al reported that epidural sufentanil for post-thoracotomy analgesia caused dose-dependent respiratory depression without significantly prolonging analgesia duration.25 Zhang et al demonstrated that sufentanil was an independent risk factor for PONV in patients undergoing video-assisted thoracoscopic surgery under general anaesthesia with preoperative thoracic paravertebral block, and the risk increased in a dose-dependent manner when the intraoperative time-weighted average sufentanil dose exceeded 0.21 µg/kg/hour.26 In clinical guidelines, Gan et al emphasised that the risk of PONV in thoracic surgery patients receiving sufentanil may reach 25%–30%, and recommended implementing a multimodal antiemetic strategy.27 In contrast, as a novel biased μ-opioid receptor agonist, tegileridine offers a theoretical advantage by providing potent analgesia while potentially reducing adverse effects related to the β-arrestin pathway, particularly respiratory depression, a major concern in opioid-based analgesia after thoracic surgery, which is also associated with an increased risk of pulmonary infection.1315 This mechanism may enable analgesia without respiratory depression. However, high-quality clinical evidence supporting its use in thoracic surgery patients remains lacking. Therefore, this study adopts a non-inferiority controlled trial design to directly compare the efficacy and safety of tegileridine versus sufentanil for PCIA, under standardised ICNB, aiming to address the evidence gap for this combination in this population. The study focuses on evaluating the analgesic efficacy and safety of the tegileridine-based regimen during the critical 48-hour postoperative period, systematically monitors drug-related adverse events and postoperative recovery quality, and thereby provides robust evidence-based insights for pain management after thoracic surgery. This study is designed with careful consideration of several key clinical elements. First, aside from the difference in postoperative analgesic drugs (tegileridine vs sufentanil), all other interventions—including the ICNB protocol—are identical between the experimental and control groups. By applying equivalent dose conversion, the analgesic efficacy and pharmacodynamic differences between the two drugs are directly compared, enabling a scientific evaluation of their cost-effectiveness. The follow-up period is set at 48 hours postoperatively to cover the peak phase of postoperative pain, ensuring patient safety and comfort. Second, the use of low-dose background infusion in PCIA helps improve patient comfort and sleep quality, assessed using the Athens Insomnia Scale. In thoracic surgery, drugs with a similar mechanism of action to tegileridine, such as oliceridine, a G protein-biased μ-opioid receptor agonist, have been shown to enhance analgesia and improve postoperative sleep quality when combined with regional nerve blocks.28 29 The half-life of oliceridine is approximately 3–5 hours, while that of tegileridine is 5–7 hours. Through a continuous background infusion design, this study further strengthens the potential advantages of such agents in maintaining sleep continuity. Additionally, the study systematically evaluates analgesic efficacy (VAS scores, use of rescue analgesia) and safety outcomes (respiratory depression, PONV) to comprehensively characterise the risk–benefit profile. Rehabilitation-related indicators, including time to ambulation and recovery of gastrointestinal function, are also included to provide clinical evidence on the impact of pain management on postoperative recovery. If non-inferiority is confirmed, tegileridine will offer a safer analgesic alternative compared with sufentanil for patients with hepatic or renal impairment, especially elderly individuals or those with mild organ dysfunction. This is because tegileridine is metabolised via esterase-mediated pathways independent of cytochrome P450, resulting in inactive metabolites that are renally excreted without contributing additional toxicity.1315 Demonstration of non-inferiority will have significant clinical relevance: tegileridine will provide analgesia comparable to sufentanil while reducing typical opioid-related adverse effects (eg, PONV, respiratory depression), supporting early recovery and lowering complication risks—advantages consistent with ERAS principles. This study will provide a foundation for further clinical investigation. If tegileridine shows effective analgesia and good safety in patients undergoing thoracoscopic pulmonary resection, future studies may extend to other major surgeries and higher-risk populations. Evaluating long-term outcomes, such as chronic pain prevention and reduced long-term opioid use, will also be valuable. Ultimately, incorporating tegileridine into an ERAS-based multimodal analgesia approach will help assess its role in improving perioperative management and patient prognosis. Supplementary material